

2771-515-CIP

RECEIVED
CENTRAL FAX CENTER
OCT 05 2006

REMARKS

Claims 1, 3-11 and 13-25 and new claims 26-40 are pending. Claims 2 and 12 have been cancelled without prejudice. Claims 16-25 have been previously withdrawn. Various claims have been amended for reciting proper antecedent basis. New claims 26-40 are directed to certain embodiments of the invention. No new matter (35 USC § 132) has been introduced.

Objection to Claim 5

Claim 5 is objected to and otherwise indicated to be allowable. In response, Applicants have amended claim 5 into independent form.

In view of the foregoing amendment of claim 5 into independent form, Applicants respectfully request allowance of claim 5 as it now stands.

Rejections Under 35 USC § 102(b) and 35 USC § 103(a)

Claims 1-4 and 6-15 are rejected under 35 USC § 102(b) as being anticipated by or, in the alternative, obvious under 35 USC § 103(a) over Blohm et al (US Pat No. 5,281,686; hereinafter "Blohm") for the reasons noted in pages 2-3 of the final Office Action.

Since Applicants have already cancelled claims 2 and 12, Applicants remarks below are directed to the rejection of 1, 3-4, 6-11 and 13-15 because the rejection of cancelled claims 2 and 12 is now moot. In response to the above-noted rejections over Blohm, Applicants have amended claim 1 (and therefore claims ultimately depending therefrom including claims 3-4, 6-11 and 13-15) to further recite the inclusion of a free radical inhibitor.

Additionally, in view of the cancellation of claims 2 and 12, claims 8 and 13-15 have been amended to depend from claim 6 instead of from cancelled claims 2 or 12. Because the Blohm patent does not disclose inclusion of a free radical inhibitor provided to stop free radical polymerization, claims 1, 3-4, 6-11, and 13-15 are not anticipated by nor rendered obvious by the Blohm reference.

Accordingly, Applicants respectfully request reconsideration and withdrawal of the aforementioned rejections of claims 1, 3-4, 6-11 and 13-15 over Blohm under 35 USC § 102(b) or 35 USC § 103(a).

New Claims 26-40

Note that new claims 26-40 do not encompass the combination of OMCTS together with bis(trimethylsiloxy)methylsilane. Also, the various features recited in claims 26-40 render these new claims patentable over Blohm. Accordingly, these new claims are also patentable over the Blohm patent.

2771-515-CIP

CONCLUSION

In view of the foregoing, Applicants respectfully request an indication of the allowance of claims 1, 3-4, 5, 6-11, 13-15 and 26-40. Applicants also respectfully request rejoinder of withdrawn claims 16-25 under MPEP § 821.04 *et seq.*

If anything further is necessary to expedite prosecution and allowance of the above-noted claims, the Examiner is respectfully requested to contact the undersigned at the address and telephone number noted below.

As already noted, Applicants submit herewith a Request for Continued Examination (RCE) and the necessary RCE fee (\$790.00) plus excess claims fee for 15 new claims less 2 claims cancelled one of which was cancelled independent claim 2 ($\$25.00 \times 13 = \325) for a total of \$1115.00.

No additional fees are believed to be due. However, should any additional fees be required or an overpayment of fees made, please debit or credit our Deposit Account No. 08-3284 – as needed.

Respectfully submitted,

October 5, 2006

Date



Ajay S. Pathak
Reg. No. 38,266
Attorney for Applicants

Enclosures:

RCE Form

Credit Card Authorization form for paying fees totaling \$1115.00

INTELLECTUAL PROPERTY/
TECHNOLOGY LAW
Phone: (919) 419-9350
Fax: (919) 419-9354
Attorney File No.: 2771-515-CIP

The USPTO is hereby authorized to charge any deficiency or credit any overpayment of fees properly payable for this document to Deposit Account No. 08-3284